New Drugs FDA Approves Kalydeco (ivacaftor) for Cystic Fibrosis in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene 8 years ago
Pharma Industry News Daily Brief: DeepMind and NHS success in AI, Bayer invests in COPD, Alecensa OK in Scotland 8 years ago